Dr. Choo Gim Hooi, Assoc Prof. Pattarapong Makarawate, Dr. Krisada Sastravaha, 20181217100000
Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa®).
Despite risk factors for cardiovascular disease (CVD) being similar around the world, the burden of CVD is not uniform across nations. Furthermore, CVD-related death in low- to middle-income countries (LMICs) has increased by two-thirds in the last 30 years, and now account for a whopping 80% of global deaths due to CVD.
Poor adherence to statin therapy is leaving many patients with dyslipidaemia at high risk of potentially life-threatening cardiovascular events. Statins are the current standard of care for reducing the risk of cardiovascular disease in these patients and for improving life expectancy, with possible economic benefits for healthcare systems too. However, many patients with dyslipidaemia are not achieving or maintaining treatment targets because they fail to stick to their prescribed statin therapy. An article co-authored by lipidologist Peter Lansberg, and published in Vascular Health and Risk Management, considers this issue and reviews approaches to overcome non-adherence.
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
Through a cardiology webcast co-hosted by Pfizer, the National Heart Association of Malaysia (NHAM), and the American College of Cardiology (ACC), Dr Ong Mei Lin, Dr Aaron D. Kugelmass and Dr Tracy Wang shared their insights into the importance of secondary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 20181011035429
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
Ischaemic heart disease was the principal cause of death in Malaysia in 2016, and ST-segment elevation myocardial infarction (STEMI) is noted as the deadliest clinical presentation of Acute Coronary Syndrome. At the National Heart Association of Malaysia’s 2018 Annual Scientific Meeting, Professor Dr Wan Azman Wan Ahmad shared his insights into the management of STEMI in Malaysia, highlighting the implications of the recent TREAT trial.